European regulators OK Alzheimer's treatment Leqembi after initial doubts
- The European Commission approved lecanemab to treat Alzheimer's, making it the first therapy to receive a marketing authorization in the EU.
- Lecanemab is the first treatment option in the EU that can slow the progression of early Alzheimer's disease.
- This decision applies to all 27 EU member states and Norway, Iceland, and Liechtenstein.
- Shares of Biogen rose about $2 to $119 in premarket trading following the approval.
133 Articles
133 Articles
Immune-system strategy used to treat cancer may help with Alzheimer’s — Harvard Gazette
Vijay Kuchroo.Veasey Conway/Harvard Staff Photographer Health Immune-system strategy used to treat cancer may help with Alzheimer’s Turning off checkpoint molecules freed microglia to attack plaques in brain, improved memory in mice Alvin Powell Harvard Staff Writer April 18, 2025 7 min read A new study raises the odds that a strategy already successful against some cancers may be deployed …
Leqembi has been granted a marketing authorisation in the European Union to treat the early stages of Alzheimer's disease. However, it will not be accessible to all patients.
European Regulators Ok Alzheimer’s Treatment Leqembi After Initial Doubts
HYANNIS – European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer and then reconsidered it. The infused treatment from Japanese drugmaker Eisai and Biogen received approval for patients in early stages of the fatal, mind-robbing disease. The decision applies to all 27 members of the […] The post European Regulators Ok Alzheimer’s Treatment Leqembi After Initi…
The European Commission has just approved the placing on the market of lecanemab (Leqembi®), a treatment for people with Alzheimer's disease at an early stage aimed at slowing down cognitive decline. The Vaincre Alzheimer Foundation sees it as a "major step forward".
Coverage Details
Bias Distribution
- 45% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium


























